BioDelivery Sciences International Inc (BDSI)

2.35
0.10 4.08
NASDAQ : Health Care
Prev Close 2.45
Open 2.50
Day Low/High 2.35 / 2.55
52 Wk Low/High 1.86 / 9.32
Volume 867.64K
Avg Volume 568.20K
Exchange NASDAQ
Shares Outstanding 55.33M
Market Cap 127.25M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Welcome to the Small-Cap Biotech Mailbag!

Welcome to the Small-Cap Biotech Mailbag!

We answer recent reader questions about three of the biotech stocks we regularly cover.

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Top 2017 Pick: Progenics Pharmaceuticals

Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher next year.

Endo International Is Top 'Dog of the S&P 500'

Endo International Is Top 'Dog of the S&P 500'

There are more dogs on the S&P 500 than on the Dow. Here's one example.

BioDelivery Sciences Announces Clonidine Topical Gel For Painful Diabetic Neuropathy Phase 2b Trial Fails To Meet Its Primary Efficacy Endpoint

BioDelivery Sciences Announces Clonidine Topical Gel For Painful Diabetic Neuropathy Phase 2b Trial Fails To Meet Its Primary Efficacy Endpoint

BDSI discontinues plan for further development resulting in an anticipated $16 million in operating plan savings in 2017 that extends cash runway

BioDelivery Sciences Reacquires License To BELBUCA™ From Endo Pharmaceuticals

BioDelivery Sciences Reacquires License To BELBUCA™ From Endo Pharmaceuticals

BELBUCA expected to be accretive to BDSI's 2017 net income and EPS

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

Small Biotechs on My Shopping List

Small Biotechs on My Shopping List

These small-caps are woefully undervalued after getting shellacked in October.

BioDelivery Sciences Announces Preferred Formulary Status For BUNAVAIL On Texas Medicaid

BioDelivery Sciences Announces Preferred Formulary Status For BUNAVAIL On Texas Medicaid

BUNAVAIL moved from non-formulary to preferred status

BioDelivery Sciences Announces Additions To Its Board Of Directors

BioDelivery Sciences Announces Additions To Its Board Of Directors

Timothy C. Tyson joins BDSI's board as an independent member with over 30 years of pharmaceutical experience

BioDelivery Sciences Cites Impressive Number Of Physicians Granted Waiver To Increase Patient Limit For Opioid Dependence Treatment Following Recent HHS Rule

BioDelivery Sciences Cites Impressive Number Of Physicians Granted Waiver To Increase Patient Limit For Opioid Dependence Treatment Following Recent HHS Rule

SAMHSA Reports 1,665 Clinicians Granted Waivers at the Increased Limit as of This Week

3 Stocks for Growth in 2017

3 Stocks for Growth in 2017

BioDelivery Sciences, Progenics Pharma and Sequential Brands are off-the-radar small-caps poised for a big year in 2017.

BioDelivery Sciences (BDSI) Stock Jumps on Ratings Upgrade

BioDelivery Sciences (BDSI) Stock Jumps on Ratings Upgrade

BioDelivery Sciences' (BDSI) stock rating was boosted at Janney Capital on Friday.

First Week Of August 19th Options Trading For BioDelivery Sciences International (BDSI)

First Week Of August 19th Options Trading For BioDelivery Sciences International (BDSI)

Investors in BioDelivery Sciences International Inc saw new options begin trading this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BDSI options chain for the new August 19th contracts and identified the following call contract of particular interest.

Profiting on Small-Cap Biotech Earnings

Don't trade the headline numbers, but cash in on those traders that do.

These 7 Stocks Under $10 Are Breaking Out

These 7 Stocks Under $10 Are Breaking Out

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

M&A Could Ignite Next Leg Up for Biotech

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.

Revisiting 3 Promising Small Biotechs

They are oversold and lately been on the move.